FDA OKs Fuji's FCRm system
Among top-selling U.S. drugs
Retinal disease strikes thousands annually
Improved patient survival in trials
When standard therapy fails
Sprycel benefits patients resistant to other drugs, including Gleevec
Already sanctioned for Alzheimer's
Experts call the change overdue, given the accumulated evidence
2nd-best selling cholesterol drug in U.S.
Reduces span when symptoms return as medicines wear off
Extended survival by nearly 3 months
For people with history of the winter blues
But doesn't end need for Pap testing, FDA warns
They won't help patients, but could shield drug makers from legal action, researchers say
Restrictions apply after Tysabri was pulled from the market last year
It's recommended for those 60 years of age and older
Vaccine prevented 50 percent of cases in people older than 60
Prevents breakdown of key brain chemical
Bausch & Lomb's ReNu MoistureLoc linked to dangerous fungal infections
Chantix more effective than Zyban in clinical trials, agency says
Curbs nicotine withdrawal symptoms
Younger, more active people benefit most, maker says
New study contradicts earlier research with rats that found a link to cancer
Using medicines for non-approved reasons is legal but risky, experts say
Some with MDS need frequent blood transfusions
Cardiac group asks FDA and manufacturers to cooperate on pacemakers, defibrillators
But votes on drug approvals wouldn't change much if they withdrew from advisory panels, study finds
While supporters laud stance, opponents call drug a valuable tool
Alerts user when glucose drops too low
Despite controversy, decades-long study finds no link
Injectable form replaces need for daily pill
Antioxidants don't seem to drive probucol's effects, study finds
Already approved for sun-damaged skin
In U.S. study, it surpassed standard anti-rejection drug
Relenza already sanctioned to treat flu's symptoms
'Surrogate markers' could speed drugs to patients, experts say
Most research on safety issues has been conducted in children, they note
Instead calls for simpler language and more information on labeling
For people who can't tolerate liquid preparations
For women who have abnormal Pap test
Panelists agree benefits outweigh rare risk of brain infection
First new drug for these types of cancer in decades
Woman who died from rare infection shouldn't have been part of Tysabri study in first place, they note
But some risk exists so more evaluation is needed, experts say
In cases where other drugs don't work
Higher doses require dietary restrictions
Treats nasal allergy symptoms
Eraxis fights deadly blood infections common at hospitals
FDA elaborates on saccharin and aspartame
But others say Tysabri, now withdrawn from market, met standard data requirements